- Home
- PEW vs ENTA Comparison
PEW vs ENTA Comparison
Compare PEW & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEW
- ENTA
- Stock Information
- Founded
- PEW 2007
- ENTA 1995
- Country
- PEW United States
- ENTA United States
- Employees
- PEW N/A
- ENTA N/A
- Industry
- PEW Other Specialty Stores
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- PEW Consumer Discretionary
- ENTA Health Care
- Exchange
- PEW Nasdaq
- ENTA Nasdaq
- Market Cap
- PEW 156.5M
- ENTA 164.6M
- IPO Year
- PEW N/A
- ENTA 2013
- Fundamental
- Price
- PEW $4.72
- ENTA $10.54
- Analyst Decision
- PEW Strong Buy
- ENTA Strong Buy
- Analyst Count
- PEW 1
- ENTA 5
- Target Price
- PEW $8.25
- ENTA $21.00
- AVG Volume (30 Days)
- PEW 648.7K
- ENTA 757.5K
- Earning Date
- PEW 11-13-2025
- ENTA 11-24-2025
- Dividend Yield
- PEW N/A
- ENTA N/A
- EPS Growth
- PEW N/A
- ENTA N/A
- EPS
- PEW N/A
- ENTA N/A
- Revenue
- PEW $90,690,000.00
- ENTA $64,806,000.00
- Revenue This Year
- PEW N/A
- ENTA $0.07
- Revenue Next Year
- PEW $6.69
- ENTA N/A
- P/E Ratio
- PEW $44.33
- ENTA N/A
- Revenue Growth
- PEW N/A
- ENTA N/A
- 52 Week Low
- PEW $4.26
- ENTA $4.09
- 52 Week High
- PEW $21.40
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- PEW 45.80
- ENTA 50.60
- Support Level
- PEW $4.35
- ENTA $10.20
- Resistance Level
- PEW $4.97
- ENTA $11.59
- Average True Range (ATR)
- PEW 0.23
- ENTA 0.58
- MACD
- PEW 0.06
- ENTA -0.19
- Stochastic Oscillator
- PEW 68.33
- ENTA 14.30
About PEW GrabAGun Digital Holdings Inc. Common Stock
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition, and related accessories.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.